Mayo Clinic Laboratories and Amprion announce collaboration to advance neurodegenerative disease diagnostics

ROCHESTER, Minn. and SAN DIEGO, March 26, 2025 – Mayo Clinic Laboratories and Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the United States. The test (test ID ASYNC) is available today for clients of Mayo Clinic Laboratories through the collaboration that combines the expertise of both organizations to enhance patient care and improve diagnostic accuracy for neurodegenerative diseases.

Amprion's SAAmplify™–αSYN (CSF) test has gained attention as a reliable laboratory-based test that aids in the diagnosis of synucleinopathies, including Parkinson's disease (PD), Lewy body dementia (LBD), multiple system atrophy (MSA), and Alzheimer’s disease + DLB. This test can identify the presence of alpha-synuclein pathology several years before overt clinical features of PD, LBD, or MSA appear, providing a critical tool for early diagnosis and differentiation from other conditions such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP). The assay is also the only seed amplification assay commercially available to detect synucleinopathies in CSF.

"By combining Mayo Clinic Laboratories' extensive expertise in diagnostic testing with Amprion's innovative SAAmplify–αSYN technology, we are expanding our portfolio of diagnostic services for neurodegenerative diseases," said William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories. "This collaboration on neurological testing enhances our ability to deliver precise and timely answers to patients and healthcare providers."

“SAAmplify offers a sensitive and specific test for synucleinopathies. This collaboration is exciting as it will increase patient access to this assay,” added Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. “Earlier detection means earlier intervention, giving patients a better chance at improved outcomes and quality of life. This is a commitment to changing lives.”

Amprion's seed amplification (SAA) technique is well-validated and accurate, offering 96% sensitivity and 92% specificity in the detection of α-synuclein pathology. The test is designed for high throughput and provides critical insights for healthcare providers, enabling more accurate diagnoses and better treatment decisions. The inclusion of this biomarker in diagnostic criteria for non-AD pathology will give physicians more confidence in their diagnoses and improve patient outcomes.

The collaboration between Mayo Clinic Laboratories and Amprion is designed to equip healthcare providers with an expanded set of important tools to make well-informed decisions and create tailored treatment plans for their patients.

Mayo Clinic Laboratories is a for-profit, wholly owned subsidiary of Mayo Clinic. Mayo Clinic has an indirect financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue received to support Mayo Clinic’s not-for-profit mission in patient care, education, and research.

About Mayo Clinic Laboratories 

Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for over 3,100 healthcare clients in partnership with Mayo Clinic's Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,200 tests and pathology services and performs more than 31 million tests annually.

About Amprion

Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion’s intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN biomarker test (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies associated with Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with Lewy body co-pathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at https://ampriondx.com/ or find us on LinkedIn.  

Contact
Mayo Clinic: newsbureau@mayo.edu

Amprion: Liz Robinson, CG Life, Amprion@cglife.com